Document Detail


Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a Phase I multicentre trial in patients scheduled for elective breast cancer surgery.
MedLine Citation:
PMID:  23315029     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Olaparib (AZD2281) is an oral poly(ADP-ribose) polymerase (PARP) inhibitor with antitumour activity in cancer patients with BRCA1/2 germline mutations and in patients with homologous recombination deficiency. In this dose-finding study, patients were randomized to olaparib 10, 30, 100, 200 or 400 mg (capsule formulation) twice daily for the 4-5 days preceding breast cancer surgery. The primary objective was to identify an effective biological dose of olaparib for future trials. Secondary endpoints included evaluation of PARP-1 inhibition dose/exposure-response, and safety. Olaparib plasma pharmacokinetics (PK) and the pharmacodynamics (PD) in tumour and peripheral blood mononuclear cells (PBMCs) were evaluated. Population PK/PD modelling was performed on pooled data from this study and a previously reported study. Sixty patients were randomized (n = 12, each dose). Dose-dependent increases in exposure to olaparib were observed, but at ~50 % lower plasma exposure levels than seen in advanced disease studies. The mean maximal extent of PARP inhibition in PBMCs and tumour tissue was 50.6 % and 70.0 %, respectively, and was similar to inhibitory levels reported previously. No PARP inhibition-dose relationship was observed. Due to the unexpectedly low olaparib exposure, we were unable to determine an effective biological dose. Common adverse events included procedural pain (n = 31 patients), nausea, asthenia, malaise and increased blood creatinine (n = 6, each); these were of mild-to-moderate intensity, and all were manageable. Despite low olaparib exposure, PARP inhibition was consistent with previous reports. Reasons for the inter-study differences in exposure are unclear. The tolerability profile of olaparib was consistent with previous studies.
Authors:
Nigel Bundred; Janis Gardovskis; Janusz Jaskiewicz; Janis Eglitis; Viktor Paramonov; Peter McCormack; Helen Swaisland; Maria Cavallin; Tony Parry; James Carmichael; J Michael Dixon
Related Documents :
2714719 - Two-year drinking-water study of formaldehyde in rats.
10367349 - Localization and comparative toxicity of methylsulfonyl-2,5- and 2,6-dichlorobenzene in...
25207569 - Imrt and rapidarc commissioning of a truebeam linear accelerator using tg-119 protocol ...
112629 - Action of psychoactive drugs on sex-related differences of of1 mice; intraspecific aggr...
14976349 - Neurotoxicity produced by dibromoacetic acid in drinking water of rats.
1799379 - Single dose toxicity study on catena-(s)-[mu-[n alpha-(3-aminopropionyl) histidinato(2-...
19429669 - Effects of remifentanil on cardiovascular and bispectral index responses to endotrachea...
3486709 - Ability of cyclophosphamide in the absence of cross-linking activity to exert the immun...
7995019 - Amphetamine-like effect of l-deprenyl (selegiline) in drug discrimination studies.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-13
Journal Detail:
Title:  Investigational new drugs     Volume:  -     ISSN:  1573-0646     ISO Abbreviation:  Invest New Drugs     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-1-14     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8309330     Medline TA:  Invest New Drugs     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Department of Academic Surgery, Education and Research Centre, University Hospital of South Manchester, Wythenshawe, M23 9LT, Manchester, UK, bundredn@manchester.ac.uk.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Phase I trial of bortezomib and dacarbazine in melanoma and soft tissue sarcoma.
Next Document:  Effect of the drug transporters ABCG2, Abcg2, ABCB1 and ABCC2 on the disposition, brain accumulation...